Aclaris Therapeutics (ACRS)
(Delayed Data from NSDQ)
$1.13 USD
-0.05 (-4.24%)
Updated Jun 17, 2024 04:00 PM ET
After-Market: $1.14 +0.01 (0.88%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
Aclaris Therapeutics, Inc. [ACRS]
Reports for Purchase
Showing records 21 - 29 ( 29 total )
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Zunsemetinib Mid-Stage Trial Details; Portfolio Expansion; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Broadened Pipeline Becomes Apparent; 3Q21 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
New Boxed Warnings for JAK Inhibitors May Benefit ATI-1777; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Multiple Candidates Advancing; 2Q21 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Positive ATI-1777 Top-Line Phase 2a Data; Cash Replenished; Raising PT to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
ATI-450 Target Indications Broaden; 1Q21 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Managing Autoimmunity by Nuanced Kinase Inhibition; Initiate at Buy and $40 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Managing Autoimmunity by Nuanced Kinase Inhibition; Initiate at Buy and $40 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R